Products
Research Areas
COVID-19
Resources
Login
Quick Order
Cart
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Contact Us

Locations


Orders Processing,
Shipping & Receiving,
Warehouse

2 Shaker Rd Suites
B001/B101
Shirley, MA 01464


Production Lab

Floor 6, Suite 620
20700 44th Avenue W
Lynnwood, WA 98036

Telephone Numbers



Tel: +1 (206) 374-1102
Fax: +1 (206) 577-4565

Contact Us



Additional Contact Details

Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Catalog Number Size Price
LS-G47191-200 200 µg $633 
KDR / VEGFR2 / FLK1 Protein - Measured by its ability to inhibit VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC) in the presence of 10 ng/mL rhVEGF165. The ED50 for this effect is 20-80 ng/mL.
KDR / VEGFR2 / FLK1 Protein
KDR / VEGFR2 / FLK1 Protein - Measured by its ability to inhibit VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC) in the presence of 10 ng/mL rhVEGF165. The ED50 for this effect is 20-80 ng/mL.
KDR / VEGFR2 / FLK1 Protein
1 of 2
2 of 2

Human KDR / VEGFR2 / FLK1 Protein (Recombinant Human IgG Fc, C-terminus) (Asp120-Lys327) - LS-G47191

Human KDR / VEGFR2 / FLK1 Protein (Recombinant Human IgG Fc, C-terminus) (Asp120-Lys327) - LS-G47191

Description:
KDR / VEGFR2 / FLK1 Protein LS-G47191 is a Recombinant Human KDR / VEGFR2 / FLK1 produced in HEK 293 Cells Asp120-Lys327 with Human IgG Fc, C-terminus tag(s). It is biologically active and is low in endotoxin; Less than 1.0 EU/µg protein (determined by LAL method). For Research Use Only
Price
Catalog Number
$633
LS-G47191-200
Toll Free North America
206-374-1102
For Research Use Only

Overview

Description:
KDR / VEGFR2 / FLK1 Protein LS-G47191 is a Recombinant Human KDR / VEGFR2 / FLK1 produced in HEK 293 Cells Asp120-Lys327 with Human IgG Fc, C-terminus tag(s). It is biologically active and is low in endotoxin; Less than 1.0 EU/µg protein (determined by LAL method). For Research Use Only

Specifications

Type
Recombinant Protein
Target
KDR / VEGFR2 / FLK1
Synonyms
KDR | CD309 | Fetal liver kinase 1 | Fetal liver kinase-1 | FLK-1 | FLK1 | Kinase insert domain receptor | Quek1 | VEGFR | VEGFR2 | Soluble VEGFR2 | VEGF receptor 2 | VEGFR-2 | CD309 antigen | VEGF-R2
Species
Human
Modifications
Unmodified
Conjugations
Unconjugated
Applications
  • Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis
Tag
Human IgG Fc, C-terminus
Region
Asp120-Lys327
Predicted Molecular Weight
The recombinant human KDR consists of 449 amino acids and predicts a molecular mass of 50.4 kDa.
Expression System
HEK 293 Cells
Source Species
Human
Purification
> 95 % as determined by SDS-PAGE.
Bio-Activity
Measured by its ability to inhibit VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC) in the presence of 10 ng/mL rhVEGF165. The ED50 for this effect is 20-80 ng/mL.
Endotoxin
Less than 1.0 EU/µg protein (determined by LAL method).
Presentation
Lyophilized from sterile PBS, pH 7.4, with 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Reconstitution
Please refer to included instructions for detailed information.
Storage
Aliquot and store at -20°C to -80°C for one year. Avoid repeated freeze-thaw cycles.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This protein carries the LSBio 100% Guarantee.
LSBio Guarantee
About KDR / VEGFR2 / FLK1
P35968 NM_002253 NP_002244.1

Publications (0)

Customer Reviews (0)

Images

Proliferation

KDR / VEGFR2 / FLK1 Protein - Measured by its ability to inhibit VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC) in the presence of 10 ng/mL rhVEGF165. The ED50 for this effect is 20-80 ng/mL.
Measured by its ability to inhibit VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC) in the presence of 10 ng/mL rhVEGF165. The ED50 for this effect is 20-80 ng/mL.

Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis

KDR / VEGFR2 / FLK1 Protein

Proliferation

KDR / VEGFR2 / FLK1 Protein - Measured by its ability to inhibit VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC) in the presence of 10 ng/mL rhVEGF165. The ED50 for this effect is 20-80 ng/mL.
Measured by its ability to inhibit VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC) in the presence of 10 ng/mL rhVEGF165. The ED50 for this effect is 20-80 ng/mL.

Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis

KDR / VEGFR2 / FLK1 Protein

Proliferation

KDR / VEGFR2 / FLK1 Protein - Measured by its ability to inhibit VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC) in the presence of 10 ng/mL rhVEGF165. The ED50 for this effect is 20-80 ng/mL.
Measured by its ability to inhibit VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC) in the presence of 10 ng/mL rhVEGF165. The ED50 for this effect is 20-80 ng/mL.

Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis

KDR / VEGFR2 / FLK1 Protein

Proliferation

KDR / VEGFR2 / FLK1 Protein - Measured by its ability to inhibit VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC) in the presence of 10 ng/mL rhVEGF165. The ED50 for this effect is 20-80 ng/mL.
Measured by its ability to inhibit VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVEC) in the presence of 10 ng/mL rhVEGF165. The ED50 for this effect is 20-80 ng/mL.

Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis

KDR / VEGFR2 / FLK1 Protein

Request SDS/MSDS

To request an SDS/MSDS form for this product, please contact our Technical Support department at:

Technical.Support@LSBio.com

Requested From: United States
Date Requested: 4/23/2024